1285 VALIDATION OF A NOVEL DIAGNOSTIC SIGNATURE FOR THE DETECTION OF BLADDER CANCER IN VOIDED URINE SAMPLES (2013)

You have accessJournal of UrologyBladder Cancer: Detection & Screening1 Apr 20131285 VALIDATION OF A NOVEL DIAGNOSTIC SIGNATURE FOR THE DETECTION OF BLADDER CANCER IN VOIDED URINE SAMPLES Makito Miyake, Steven Goodison, Myron Chang, Yunfeng Dai, Lourdes Mengual, Virginia Urquidi, and Charles J. Rosser Makito MiyakeMakito Miyake Orlando, FL More articles by this author , Steven GoodisonSteven Goodison Orlando, FL More articles by this author , Myron ChangMyron Chang Gainesville, FL More articles by this author , Yunfeng DaiYunfeng Dai Gainesville, FL More articles by this author , Lourdes MengualLourdes Mengual Barcelona, Spain More articles by this author , Virginia UrquidiVirginia Urquidi Orlando, FL More articles by this author , and Charles J. RosserCharles J. Rosser Orlando, FL More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2639AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Accurate urinary assays for bladder cancer (BCa) detection would benefit both patients and healthcare systems. Through genomic and proteomic profiling of urine components, we have previously identified a panel of biomarkers that can outperform current urine-based biomarkers for the non-invasive detection of BCa. Herein, we report the diagnostic utility of various multivariate combinations of these biomarkers. METHODS We performed a case-controlled validation study in which voided urines from 127 patients (64 tumor bearing subjects) were analyzed. The urinary concentrations of 14 biomarkers (Interleukin-8 (IL-8), Matrix metalloproteinase-9 (MMP-9), Matrix metalloproteinase-10 (MMP-10), Syndecan 1 (SDC1), Chemokine (C-C motif) ligand 18 (CCL18), plasminogen activator inhibitor-1 (PAI-1), CD44, vascular endothelial growth factor (VEGF), Angiogenin (ANG), Carbonic anhydrase 9 (CA9), Alpha 1-Antitrypsin (A1AT), Osteopontin (OPN), Pentraxin3 (PTX3), and Apolipoprotein E (APOE)) were assessed by enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test. RESULTS An 8-biomarker diagnostic signature achieved the most accurate BCa diagnosis (sensitivity 92%, specificity 97%). Subsequently, the validate diagnostic signature was tested by ELISA in an independent cohort of 308 patients (102 tumor bearing subjects and 206 diverse controls including UTI, stones, voiding symptoms, hematuria and normals). The 8-biomarker diagnostic signature was accurate in diagnosing BCa in voided urine samples (sensitivity 88%, specificity 91%). CONCLUSIONS These data show that a multivariate urine-based assay can markedly improve the accuracy of non-invasive BCa detection. Further validation studies are under way to investigate the clinical utility of this panel of biomarkers for BCa diagnosis and disease monitoring. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e525-e526 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Metrics Author Information Makito Miyake Orlando, FL More articles by this author Steven Goodison Orlando, FL More articles by this author Myron Chang Gainesville, FL More articles by this author Yunfeng Dai Gainesville, FL More articles by this author Lourdes Mengual Barcelona, Spain More articles by this author Virginia Urquidi Orlando, FL More articles by this author Charles J. Rosser Orlando, FL More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...